

**INFORMATION ABOUT THE FACTS AND CIRCUMSTANCES OCCURRED  
DURING THE FIRST QUARTER OF 2026  
OF "SOPHARMA" AD**

**Annex № 4**

**To Art. 12, par. 1, it.1, art.14 of Ordinance № 2 from 09.11.2021  
And Regulation (EU) 596/2014 of the European Parliament and of the Council  
of 16 April 2014**

*The persons who are liable for damages caused by false, misleading or incomplete data in this information as of 31.03.2026 are:*

*Ognian Donev - Executive Director and Chairman of the Board of Directors of "Sopharma" AD  
Vesela Stoeva – Deputy. - Chairman of the Board of Directors of "Sopharma" AD  
Bissera Lazarova – Member of the Board of Directors of "Sopharma" AD  
Alexandar Tchaouchev – Member of the Board of Directors of "Sopharma" AD  
Ivan Badinski - Member of the Board of Directors of "Sopharma" AD*

- 1.1. No change in the persons controlling the Company.
- 1.2. No opening of bankruptcy proceedings against the company or its subsidiary or any significant events related to production.
- 1.3. There are no significant transactions.
- 1.4. No decision on conclusion, termination and cancellation of joint venture agreements.
- 1.5. Change of the auditors of the company - No change of auditors.
- 1.6. There is no opening or termination of a court or arbitration case relating to the debts or claims of the company or its subsidiary with a claim price of at least 10% of the company's equity.
- 1.7. There is no purchase, sale or established pledge of equity interests in commercial companies by the issuer or its subsidiary.
- 1.8. Management is monitoring the development of the military conflict in Ukraine, as well as the tension in the Middle East region, and assessing their impact on the business, financial condition and future prospects. The Company has commercial relationships with counterparties in Ukraine, Russia and Belarus, and Management continuously monitors the applicable sanction regimes and assesses the risks associated with them. Management has performed an analysis and has determined that no significant problems have arisen in the collection of receivables in the ordinary course of business in recent years, therefore it believes that as of the date of this report there is no indication of a direct negative impact on the transactions and operations with these counterparties, as well as on their financial stability. As of the reporting date, no significant direct effects have been identified on the Company's assets, with the possible impact being mainly indirect and expressed in increased volatility in energy and transport prices, difficulties in supply chains and pressure on costs and margins. The geopolitical environment continues to be considered a source of uncertainty.

"Sopharma" AD informs all interested parties that the individual financial statements for the first quarter of 2026 of the Company have not been verified by a registered auditor.

**Information under Art. 12, para. 1, item 2 of REGULATION No. 2 of 09.11.2021 on initial and subsequent disclosure of information during the process of public offering of securities and admission of securities to trading on a regulated market.**

Electronic reference to the place on the website of the public company, where the internal information under Art. 7 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation) and Directive 2003/6/EC of the European Parliament and of the Council and Directives 2003 /124/EC, 2003/125/EC and 2004/72/EC of the Commission (OB, L 173/1 of 12 June 2014) (Regulation (EU) No 596/2014) regarding the

circumstances that occurred in the first quarter of 2026, or an electronic reference to the issuer's chosen news agency or other media through which the company makes public the inside information:

During the period 01.01.2026 - 31.03.2026, "Sopharma" AD discloses information to the Financial Supervision Commission Authority, the Bulgarian Stock Exchange, the Warsaw Stock Exchange and the public, through the information platform x3news (<http://www.x3news.com>), through the company's corporate website in the "Investors" section (<https://www.sopharmagroup.com/bg/investitori/novini-za-investitori>), on the information site investor.bg (<https://www.investor.bg/bulletin>) and on Biznes PAP ([Biznes PAP](#)).